Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU) [Yahoo! Finance]
Novartis (NYSE:NVS) had its "hold" rating reaffirmed by analysts at TD Cowen.
Should Vanrafia Kidney Data and Dividend Move Reshape the Novartis (SWX:NOVN) Autoimmune Investment Case? [Yahoo! Finance]
Is It Too Late To Consider Novartis (SWX:NOVN) After Strong Multi-Year Share Gains? [Yahoo! Finance]
Novartis (NYSE:NVS) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.